Japan Gene Therapies Progress In Post-Zolgensma World
Otsuka, Others Move Forward In Supportive Environment
The recent reimbursement and launch of Zolgensma showed Japan willing and able to approve and pay for gene therapies, and others including from Otsuka/Takara Bio are moving forward under a supportive regulatory framework.
You may also be interested in...
Japanese company joins the ranks of big pharma buying up gene therapy pioneers
Japanese firm again links with an earlier venture capital partner and some familiar faces to progress its norovirus vaccine outside Japan.
Private California venture will bring additional expertise and novel platforms to acquisitive biotech giant as it looks to expand its interests in bispecific and multispecific antibody technologies.